Drugs · acquisition-cost intelligence
Aleve
naproxen sodium· ingredient naproxenAntiinflammatory preparations, non-steroids for topical use· NAPROXEN SODIUM 220 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.14651
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other naproxen products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Naproxen | $0.05893 | −$0.08760 |
| Naprotin | $0.06254 | −$0.08400 |
| 24/7 Life by 7-Eleven Naproxen Sodium | $0.06496 | −$0.08150 |
| Naproxen Oral Suspension | $0.17537 | +$0.02890 |
| Naproxen sodium | $0.22001 | +$0.07350 |
| Aleve-D Sinus and Cold | $0.24430 | +$0.09780 |
| Naproxen | $1.91 | +$1.76 |
| Naprelan | $9.28 | +$9.13 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.